EN DE

Abrdn Healthcare Investors (HQH) Fair Value & Analysis

Financial Services · US · Market cap $1.2B

AH Abrdn Healthcare Investors logo Abrdn Healthcare Investors HQH · US
Price$23.04
Fair Value$26.78
Upside+16.2%
Quality54/100
Watch Abrdn Healthcare Investors for free, get notified when fair value or trend changes. Watch for free
Weak Growth
negative free cash flow
11.31% dividend yield
Mixed vs. peers (4/10)
Narrow moat 38/100
Evidence: High Range $20.08 – $33.47 Share as image

Fair value as of: Jul 26, 2026

From 8 valuation models · updated 15 days ago

Share price +5.3% over the past month.

A solid business, screening 16% undervalued on our models.

What matters now

  • For a financial, book-value and earnings-based methods matter more than a cash-flow DCF, which fits banks and insurers poorly.
  • Our model range runs from $20.08 (bear) to $33.47 (bull), base $26.78. The closer the price sits to the lower half, the larger the margin of safety.
  • Quality 54/100 (solid quality) with high evidence: the data supports the verdict.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

$23.04 $10.15 Fair Value $26.78 Apr 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 26, 2026.

How to read this chart

60‑month range $10.15 – $23.04 · fair‑value band $20.08 – $33.47 · the $23.04 price screens below the $26.78 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 26, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Abrdn Healthcare Investors (HQH) currently trades at $23.04, while our model-based Fair Value estimate is $26.78, implying the stock looks roughly 16.2% undervalued today. The Quality Score stands at 54/100 (solid quality), in the Financial Services sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.

Trailing-twelve-month revenue stands at $5.5M. Revenue declined 42.1% year over year. It earns a return on equity of 24.2%. The stock trades on a trailing P/E of 4.5. Fundamentals as of Jul 26, 2026

Our scenario range runs from $20.08 (bear case) to $33.47 (bull case); at $23.04, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high and 73% above its 52-week low, currently above its 200-day average. For context, the median of 10 Financial Services peers we cover trades at -12% fair-value upside, at 16%, HQH screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model BearBaseBull Evidence
Highest evidence
Residual Income $15.40 $16.42 $18.13 76
Gordon GGM $4.24 $7.64 $10.52 70
P/E Multiple $16.81 $22.42 $28.02 63
All 8 models by family
Earnings-Based
Graham-Dodd $11.72 $81.77 $114.75 54
Lynch FV $42.24 $60.35 $78.45 50
Dividend Discount
Gordon GGM $4.24 $7.64 $10.52 70
DDM Multi-Stage $4.24 $6.98 $8.16 61
Multiples
P/E Multiple $16.81 $22.42 $28.02 63
P/B Multiple $20.08 $26.78 $33.47 55
Asset-Based
NCAV (Graham) $9.56 $12.81 $19.13 50
Economic Profit
Residual Income $15.40 $16.42 $18.13 76

Widest divergence: Earnings-Based ($60.35) versus Dividend Discount ($6.98). Highest evidence: Residual Income (76).

Key figures & financial health

Revenue (TTM) $5.5M
Revenue growth (YoY) -42.1%
Net margin 4,561%
Return on equity 24.2%
Free cash flow −$141M FY2014
P/E ratio 4.5
More key figures
Operating margin -126%
EPS (TTM) $4.47
Dividend yield 11.3%
EPS growth (YoY) +91.1%
Net cash $59 FY2025

Figures from reported company fundamentals · as of Jul 26, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 54/100

Of which business quality 53 · Market factors (momentum, volatility) 88

Profitability 44
Margins and returns on capital today
Quality Growth 48
Are margins and returns improving?
Cashflow 33
Earnings quality: real cash, not paper profit
Fin. Strength 75
Balance sheet, leverage, solvency risk
Investment 80
Disciplined investing over empire-building
Low Volatility 84
Calm price path (market factor)
Momentum 83
Price trend over the last 3–12 months (market factor)
52W Momentum 100
Distance to the 52-week high (market factor)
Net Issuance 45
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Abrdn Healthcare Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the healthcare sector, including the biotechnology, medical devices, and pharmaceuticals industries.

Full company description

Abrdn Healthcare Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the healthcare sector, including the biotechnology, medical devices, and pharmaceuticals industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as current or anticipated market position for services or products, experienced business management, recognized technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotechnology Index, the S&P 500 Index, and the S&P 1500 Healthcare Index. Abrdn Healthcare Investors was formed on October 31, 1986 and is domiciled in the United States.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Abrdn Healthcare Investors reported revenue of $99.8M in FY2025 versus $157M in FY2021, a compound −10.7%/yr. Reported net income was $98.6M in FY2025, compounding −10.7%/yr from FY2021.

Growth Quality 21/100
Revenue growth is weak, negative or inconsistent.
Latest Revenue (FY 2025)
$99.8M
Avg. growth/yr (5Y)
−16.3%
Avg. growth/yr (29Y)
+22.9%
Revenue −10.7%/yr
FY21 $157M
FY22 −$192M
FY23 $58.1M
FY24 $10.8M
FY25 $99.8M
Net income −10.7%/yr
FY21 $155M
FY22 −$194M
FY23 $56.3M
FY24 $185M
FY25 $98.6M

Watch HQH: get an alert when its fair value changes →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Abrdn Healthcare Investors Fair Value". https://www.fairvalue-calculator.com/stock/HQH

Peer Group

Asset Management · 973 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 53 · Below median
Fair Value upside +16% · Above median
Return on equity (TTM) 24% · Top 25%
Return on assets -0% · Bottom 25%
Operating margin (TTM) -126% · Bottom 25%
Revenue growth -42% · Bottom 25%
Dividend yield (TTM) 11.3% · Top 25%

Valuation Multiples vs Asset Management median · lower = cheaper

P/E (TTM) 4.5× · Cheaper than 75% of peers
P/B 1.06× · Pricier than median
EV/EBITDA 11.7× · Pricier than median

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 55 · sector 37
FUTURE 0 · sector 6
PAST 97 · sector 26
HEALTH 0 · sector 95
DIVIDEND 100 · sector 69

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Asset Management stocks, each showing price versus our Fair Value estimate (as of Jul 26, 2026).

Stock Price Fair Value vs Fair Value
Fondul Proprietatea SA FP $0.0420 $0.0800 +90%
BlackRock, Inc BLK $1,136 $465.75 -59%
Blackstone Inc BX $124.56 $16.35 -87%
Investor AB INVEB kr 423.70 kr 847.40 +100%
Brookfield Corporation BN C$62.45 C$10.12 -84%
KKR & Co KKR $100.94 $44.88 -56%
AB Industrivärden INDUA kr 532.50 kr 1,065 +100%
Jio Financial Services Limited JIOFIN ₹242.98 ₹40.19 -83%
Hedef Holding HEDEF 267.25 TRY 320.98 TRY +20%
Bajaj Holdings BAJAJHLDNG ₹10,398 ₹9,202 -12%

Compare Abrdn Healthcare Investors with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Financial Services stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Abrdn Healthcare Investors (HQH) overvalued or undervalued?
As of Jul 26, 2026, our model estimates a fair value of $26.78 versus a price of $23.04, about +16% (undervalued).
What is the fair value of HQH?
Our model-based fair value for Abrdn Healthcare Investors is $26.78 (as of Jul 26, 2026), built from audited fundamentals. The current price is $23.04.
What is the quality score of HQH?
Abrdn Healthcare Investors has a Quality Score of 54/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Abrdn Healthcare Investors (HQH)?
Abrdn Healthcare Investors reported trailing-twelve-month revenue of about $5.5M (latest available figure, as of Jul 26, 2026).
Does Abrdn Healthcare Investors pay a dividend?
Abrdn Healthcare Investors currently shows a dividend yield of about 11.31% relative to its recent price (as of Jul 26, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Abrdn Healthcare Investors and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.